Boston Scientific Corporation (BSX)

NYSE: BSX · Real-Time Price · USD
47.69
+0.01 (0.02%)
At close: Jun 3, 2026, 4:00 PM EDT
47.71
+0.02 (0.04%)
After-hours: Jun 3, 2026, 7:47 PM EDT
Market Cap70.88B -54.8%
Revenue (ttm)20.61B +17.4%
Net Income3.57B +75.4%
EPS2.39 +74.4%
Shares Out 1.49B
PE Ratio19.95
Forward PE13.85
Dividendn/a
Ex-Dividend Daten/a
Volume20,434,333
Open47.81
Previous Close47.68
Day's Range47.17 - 48.59
52-Week Range47.17 - 109.50
Beta0.56
AnalystsStrong Buy
Price Target78.87 (+65.38%)
Earnings DateApr 22, 2026

About BSX

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatogra... [Read more]

Sector Healthcare
IPO Date May 18, 1992
Employees 59,000
Stock Exchange NYSE
Ticker Symbol BSX
Full Company Profile

Financial Performance

In 2025, Boston Scientific's revenue was $20.07 billion, an increase of 19.87% compared to the previous year's $16.75 billion. Earnings were $2.90 billion, an increase of 56.40%.

Financial Statements

Analyst Summary

According to 31 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price target is $78.87, which is an increase of 65.38% from the latest price.

Price Target
$78.87
(65.38% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Boston Scientific price target lowered to $65 from $80 at BTIG

BTIG analyst Marie Thibault lowered the firm’s price target on Boston Scientific (BSX) to $65 from $80 and keeps a Buy rating on the shares after updating the firm’s forecast…

1 day ago - TheFly

Boston Scientific put volume heavy and directionally bearish

Bearish flow noted in Boston Scientific (BSX) with 8,246 puts trading, or 2x expected. Most active are Jun-26 47.5 puts and 6/5 weekly 47.5 puts, with total volume in those…

1 day ago - TheFly

Boston Scientific price target lowered to $70 from $71 at Canaccord

Canaccord lowered the firm’s price target on Boston Scientific (BSX) to $70 from $71 and keeps a Buy rating on the shares. The firm updated its model to reflect slowdowns…

2 days ago - TheFly

Belo Sun Announces Corporate Update

TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTC: BSXGF) (the “Company” or “Belo Sun”) provides the following updates regarding a recent petition filed by the Brazilian...

2 days ago - GlobeNewsWire

Boston Scientific price target lowered to $61 from $80 at TD Cowen

TD Cowen lowered the firm’s price target on Boston Scientific (BSX) to $61 from $80 and keeps a Buy rating on the shares. The firm updated its model to account…

5 days ago - TheFly

Boston Scientific downgraded to Peer Perform from Outperform at Wolfe Research

Wolfe Research downgraded Boston Scientific (BSX) to Peer Perform from Outperform without a price target The firm cut the company’s estimates to reflect the Watchman guidance reduction. It now models…

5 days ago - TheFly

Boston Scientific price target lowered to $71 from $81 at Goldman Sachs

Goldman Sachs lowered the firm’s price target on Boston Scientific (BSX) to $71 from $81 and keeps a Buy rating on the shares after the companyprovided additional commentary on expectations…

6 days ago - TheFly

Boston Scientific price target lowered to $70 from $87 at Citi

Citi analyst Joanne Wuensch lowered the firm’s price target on Boston Scientific (BSX) to $70 from $87 and keeps a Buy rating on the shares. The firm cites the company’s…

6 days ago - TheFly

Boston Scientific price target lowered to $70 from $75 at Baird

Baird lowered the firm’s price target on Boston Scientific (BSX) to $70 from $75 and keeps an Outperform rating on the shares. The firm updated its model and lowered estimates…

6 days ago - TheFly

Boston Scientific price target lowered to $74 from $87 at Leerink

Leerink lowered the firm’s price target on Boston Scientific (BSX) to $74 from $87 and keeps an Outperform rating on the shares.

6 days ago - TheFly

Boston Scientific price target lowered to $89 from $96 at Barclays

Barclays lowered the firm’s price target on Boston Scientific (BSX) to $89 from $96 and keeps an Overweight rating on the shares. The firm says the company yesterday set appropriate…

6 days ago - TheFly

Boston Scientific downgraded to Equal Weight from Overweight at Wells Fargo

Wells Fargo analyst Larry Biegelsen downgraded Boston Scientific (BSX) to Equal Weight from Overweight with a price target of $55, down from $75. The firm sees near-term uncertainty for the…

6 days ago - TheFly

Boston Scientific price target lowered to $75 from $85 at Stifel

Stifel analyst Rick Wise lowered the firm’s price target on Boston Scientific (BSX) to $75 from $85 and keeps a Buy rating on the shares. Boston Scientific lowered expectations for…

7 days ago - TheFly

Boston Scientific slides after flagging slowdown in Watchmen heart device usage

Boston Scientific shares fell about 12% on Wednesday to their lowest in more than two years, after the medical device ​maker flagged declining usage of its heart disease device.

7 days ago - Reuters

Here’s Why Boston Scientific Stock (BSX) Is Crashing Today

Management provided a corporate update.

Other symbols: PEN
7 days ago - TipRanks

Boston Scientific Transcript: Bernstein 42nd Annual Strategic Decisions Conference

Management reaffirmed confidence in achieving margin and EPS growth despite lowering 2024 guidance due to challenges in WATCHMAN, EP, and urology. Key growth drivers include new product launches, the Penumbra acquisition, and innovation in TAVR and mapping. Robust pipeline and disciplined capital allocation support a positive long-term outlook.

7 days ago - Transcripts

Belo Sun Announces 2026 Shareholder Meeting Voting Results and Corporate Update

TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX:BSX OTCQX:BSXGF) today is pleased to announce that each of the six individuals nominated for election...

8 days ago - GlobeNewsWire

Belo Sun Provides Update on Ongoing Proceedings Before TRF-1

TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX, OTCQX: BSXGF) is pleased to provide an update regarding hearings held yesterday before the 6th ...

13 days ago - GlobeNewsWire

Boston Scientific reports FRACTURE trial meets primary endpoint

Boston Scientific (BSX) announced results from the FRACTURE Investigational Device Exemption trial evaluating the use of the Seismiq 4CE Coronary Intravascular Lithotripsy Catheter to treat patients w...

15 days ago - TheFly

FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints

Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease MARLBOROUGH, Mass. ...

15 days ago - PRNewsWire

Boston Scientific invests $1.5 billion in MiRus with option to buy heart-valve business

U.S. medical device maker Boston Scientific said on Monday it has invested $1.5 billion in privately held ​MiRus LLC in return for a 34% equity ‌stake and potential access to the startup's heart-valve...

16 days ago - Reuters

Boston Scientific enters into $2 billion accelerated share repurchase agreement

MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase ...

16 days ago - PRNewsWire

Boston Scientific Slides: Acquisition presentation

Boston Scientific has posted slides in relation to its latest quarterly earnings report, which was published on May 18, 2026.

16 days ago - Filings

Boston Scientific announces strategic investment in MiRus LLC

Agreement includes exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloy MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientif...

16 days ago - PRNewsWire

Belo Sun to Commence Technical Studies on Volta Grande Gold Project

TORONTO, May 12, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or “Company”) (TSX: BSX, OTCQB: BSXGF) today announces the commencement of technical studies relating to its Volta Grande Go...

22 days ago - GlobeNewsWire